PLURNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Pluri Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 10, 2026
$0.85−0.08 (-8.58%)
Close on Oct 19, 2026
- Market cap
- $9.08M
- P/E (TTM)
- –
- Dividend yield
- –
Pluri statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Pluri | Industry median |
|---|---|---|
| Market Cap | $10.49M | $164.85M |
| Enterprise Value | $7.25M | $87.06M |
| PS Ratio | 10.33 | 3.60 |
Enterprise value
| Measure | Pluri | Industry median |
|---|---|---|
| EV / Sales | 7.13 | 2.43 |
Income (trailing twelve months)
| Measure | Pluri | Industry median |
|---|---|---|
| Revenue | $1.02M | $57.94M |
| Gross Profit | $453.00K | $90.47M |
| Operating Income | -$24.94M | -$21.44M |
| Pretax Income | -$25.39M | -$14.45M |
| Net Income | -$23.82M | -$22.46M |
| EBITDA | -$24.43M | -$16.91M |
Margins
| Measure | Pluri | Industry median |
|---|---|---|
| Gross Margin | 44.6% | 52.3% |
| Operating Margin | -2454.5% | -44.5% |
| Pretax Margin | -2499.4% | -13.0% |
| Profit Margin | -2344.6% | -39.2% |
| EBITDA Margin | -2404.2% | -31.3% |
| FCF Margin | -1990.3% | -8.85% |
Returns
| Measure | Pluri | Industry median |
|---|---|---|
| Return on Assets (ROA) | -75.0% | -41.0% |
Growth
| Measure | Pluri | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -24.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 52.4% | 2.25% |
Balance sheet
| Measure | Pluri | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.85M | $62.42M |
| Net Cash (Debt) | $8.85M | $15.68M |
| Net Cash Per Share | $0.72 | $0.66 |
| Equity (Book Value) | -$23.04M | $48.79M |
| Book Value Per Share | -$1.87 | $1.36 |
| Tangible Book Value | -$28.79M | $23.06M |
| Working Capital | -$23.99M | $75.77M |
Financial position
| Measure | Pluri | Industry median |
|---|---|---|
| Current Ratio | 0.27 | 3.30 |
| Quick Ratio | 0.27 | 2.39 |
| Interest Coverage | -26.76 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Pluri | Industry median |
|---|---|---|
| Operating Cash Flow | -$19.59M | -$12.35M |
| Capital Expenditures | -$633.00K | -$1.06M |
| Free Cash Flow | -$20.22M | -$20.28M |
| FCF Per Share | -$1.64 | -$0.42 |
Efficiency
| Measure | Pluri | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.38 |
| Revenue Per Employee | $11.04K | $398.96K |
| Profits Per Employee | -$258.92K | -$703.34K |
| Employee Count | 92 | 74 |
Dividends and yields
| Measure | Pluri | Industry median |
|---|---|---|
| Earnings Yield | -227.0% | -22.7% |
| FCF Yield | -192.7% | -9.07% |
| Buyback Yield | -48.4% | -0.73% |
| Shareholder Yield | -48.4% | 0.00% |
Shares
| Measure | Pluri | Industry median |
|---|---|---|
| Shares Outstanding | 12,344,700 | 58,179,650 |
| Shares Change (YoY) | 53.8% | 11.1% |
| Shares Change (QoQ) | 3.77% | 0.54% |
| Float | 3,797,030 | 49,173,100 |
| Shares Held by Insiders | 69.2% | 11.6% |
| Shares Held by Institutions | 0.22% | 59.4% |
Taxes
| Measure | Pluri | Industry median |
|---|---|---|
| Income Tax | -$25.00K | $91.50K |
Scores
| Measure | Pluri | Industry median |
|---|---|---|
| Altman Z-Score | -30.55 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Pluri's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.